1. |
Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005;113:179-88.
|
2. |
Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, et al. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 1999;289:559-64.
|
3. |
Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;8:368-79.
|
4. |
Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985;249:F490-6.
|
5. |
Ashrafi F, Haghshenas S, Nematbakhsh M, Nasri H, Talebi A, Eshraghi-Jazi F, et al. The role of magnesium supplementation in cisplatin-induced nephrotoxicity in a rat model: No nephroprotectant effect. Int J Prev Med 2012;3:637-43. [ PUBMED]
|
6. |
Ali B, Ismail TB, Bashir A. Sex difference in the susceptibility of rats to gentamicin nephrotoxicity: Influence of gonadectomy and hormonal replacement therapy. Indian J Pharmacol 2001;33:369-73.
|
7. |
Bennett WM, Parker RA, Elliott WC, Gilbert DN, Houghton DC. Sex-related differences in the susceptibility of rats to gentamicin nephrotoxicity. J Infect Dis 1982;145:370-3.
|
8. |
Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Gender difference in cisplatin-induced nephrotoxicity in a rat model: Greater intensity of damage in male than female. Nephrourol Mon 2013;5:818-21.
|
9. |
Nematbakhsh M, Talebi A, Nasri H, Safari T, Dolatkhah S, Ashrafi F. Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats. Clin Exp Med Lett 2012;53:29-32.
|
10. |
Nematbakhsh M, Nasri H. Cisplatin nephrotoxicity may be sex related. Kidney Int 2013;83:1201.
|
11. |
Nematbakhsh M, Pezeshki Z. Sex-related difference in nitric oxide metabolites levels after nephroprotectant supplementation administration against cisplatin-induced nephrotoxicity in wistar rat model: The role of Vitamin E, erythropoietin, or n-acetylcysteine. ISRN Nephrol 2013;2013:612675.
|
12. |
Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci 2011;16:1389-96. [ PUBMED]
|
13. |
Moslemi F, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Nasri H, Ashrafi F, et al. Inhibition of Nitric Oxide Synthase by L-NAME Promotes Cisplatin-Induced Nephrotoxicity in Male Rats. ISRN Toxicol 2013;2013:242345.
|
14. |
Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences. Ren Fail 2012;34:1046-51.
|
15. |
Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, Nasri H, Talebi A, Safari T, et al. Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 2013;7:383-9.
|
16. |
Jilanchi S, Nematbakhsh M, Bahadorani M, Talebi A, Eshraghi-Jazi F, Mansouri A, et al. Vitamin E is a nephroprotectant agent in male but not in female in a model of Cisplatin-induced nephrotoxicity. ISRN Nephrol 2013;2013:280395.
|
17. |
McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:30H-7.
|
18. |
Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int Suppl 1996;55:S57-62.
|
19. |
Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-40.
|
20. |
Vidhya R, Thi MJ, Agavalli U. Protective effect of captopril against cisplatin induced nephrotoxicity in rats. Pharmacol Online 2010;1:12-5.
|
21. |
El-Sayed el-SM, Abd-Ellah MF, Attia SM. Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pak J Pharm Sci 2008;21:255-61.
|
22. |
Keith DS, Torres VE, Johnson CM, Holley KE. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han: SPRD rats. Am J Kidney Dis 1994;24:491-8.
|
23. |
Hilliard LM, Nematbakhsh M, Kett MM, Teichman E, Sampson AK, Widdop RE, et al. Gender differences in pressure-natriuresis and renal autoregulation: Role of the angiotensin type 2 receptor. Hypertension 2011;57:275-82.
|
24. |
Pezeshki Z, Eshraghi-Jazi F, Nematbakhsh M. Vascular response to graded angiotensin II infusion in offspring subjected to high-salt drinking water during pregnancy: The effect of blood pressure, heart rate, urine output, endothelial permeability, and gender. Int J Vasc Med 2014;2014:876527.
|
25. |
Safari T, Nematbakhsh M. Angiotensin 1-7 receptor and angiotensin II receptor 2 blockades prevent the increased serum and kidney nitric oxide levels in response to angiotensin II administration: Gender-related difference. Int J Prev Med 2013;4:311-5. [ PUBMED]
|
26. |
Nematbakhsh M, Safari T. Role of Mas receptor in renal blood flow response to angiotensin (1-7) in male and female rats. Gen Physiol Biophys 2014;33:365-72.
|
27. |
Safari T, Nematbakhsh M, Hilliard LM, Evans RG, Denton KM. Sex differences in the renal vascular response to angiotensin II involves the Mas receptor. Acta Physiol (Oxf) 2012;206:150-6.
|
28. |
Zapater P, Novalbos J, Gallego-Sandín S, Hernández FT, Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol 2004;43:737-44.
|
29. |
Rastghalam R, Nematbakhsh M, Bahadorani M, Eshraghi-Jazi F, Talebi A, Moeini M, et al. Angiotensin type-1 receptor blockade may not protect kidney against cisplatin-induced nephrotoxicity in rats. ISRN Nephrol 2014;2014:479645.
|
30. |
Yamate J, Sato K, Machida Y, Ide M, Sato S, Nakatsuji S, et al. Cisplatin-induced rat renal interstitial fibrasis; a possible pathogenesis based on the data. J Toxicol Pathol 2000;13:237-47.
|
31. |
Hannemann J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicology 1988;51:119-32.
|
32. |
Herlitz H, Svalander C, Tarkowski A, Westberg G. Effect of captopril on murine systemic lupus erythematosus disease. J Hypertens Suppl 1988;6:S684-6.
|
33. |
Pechanova O. Contribution of captopril Thiol group to the prevention of spontaneous hypertension. Physiol Res Acad Sci Bohemoslov 2007;56 Suppl 2:S41-8.
|
34. |
Ohishi A, Suzuki H, Nakamoto H, Katsumata H, Sakaguchi H, Saruta T. Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats. Clin Sci (Lond) 1989;76:353-6.
|
35. |
Lassila M, Finckenberg P, Pere AK, Krogerus L, Ahonen J, Vapaatalo H, et al. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol 2000;130:1339-47.
|
36. |
Azzadin A, Malyszko J, Malyszko JS, Tankiewicz A, Mysliwiec M, Buczko W. Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats. Pol J Pharmacol 2002;54:469-73.
|
37. |
Guron G. Renal haemodynamics and function in weanling rats treated with enalapril from birth. Clin Exp Pharmacol Physiol 2005;32:865-70.
|
38. |
Pezeshki Z, Nematbakhsh M, Nasri H, Talebi A, Pilehvarian AA, Safari T, et al. Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovarectomized rat model. Toxicol Int 2013;20:43-7. [ PUBMED]
|
39. |
Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F, Nasri H, Talebi A, et al. Vitamin E, Vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol 2012;2012:284896.
|
40. |
Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012;2012:890310.
|
41. |
Dean SA, Tan J, O'Brien ER, Leenen FH. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R759-66.
|
42. |
Soltani N, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Effect of oral administration of magnesium on Cisplatin-induced nephrotoxicity in normal and streptozocin-induced diabetic rats. Nephrourol Mon 2013;5:884-90.
|
43. |
Mazaheri S, Nematbakhsh M, Bahadorani M, Pezeshki Z, Talebi A, Ghannadi AR, et al. Effects of fennel essential oil on cisplatin-induced nephrotoxicity in ovariectomized rats. Toxicol Int 2013;20:138-45. [ PUBMED]
|
44. |
Ohno T, Kato S, Wakatsuki M, Noda SE, Murakami C, Nakamura M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: Comparison with radiation therapy alone. Gynecol Oncol 2006;103:94-9.
|
45. |
Santos EL, de Picoli Souza K, Guimarães PB, Reis FC, Silva SM, Costa-Neto CM, et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 2008;8:247-53.
|
46. |
Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: Involvement in p53 regulation and cisplatin resistance. Br J Cancer 2008;98:1803-9.
|
47. |
Ohwada T, Ishibashi T, Yaoita H, Shindo J, Noji H, Ohkawara H, et al. Different contribution of apoptosis to the antiproliferative effects of L-arginine, enalapril and losartan on neointimal growth inhibition after balloon arterial injury. Circ J 2002;66:965-71.
|
48. |
Pezeshki Z, Nematbakhsh M. Nitric oxide metabolites change in cisplatin-induced nephrotoxicity: The effect of L-arginine and losartan. J Anal Oncol 2013;2:117-9.
|
49. |
Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res 2007;55:81-95.
|